Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ResMed Inc. Common Stock (NY:RMD)

211.94 -11.30 (-5.06%)
Official Closing Price Updated: 7:00 PM EDT, Aug 7, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ResMed Inc. Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
News headline image
ResMed Q4 Earnings Call Highlights ↗
ResMed (NYSE:RMD) reported fourth-quarter fiscal 2026 revenue growth of 9% on a reported basis, or 8% in constant currency, as demand for sleep devices and masks increased. Non-GAAP earnings per share... 
Via MarketBeat
Topics Earnings Economy
Stay informed with the top movers within the S&P500 index on Friday. ↗
Via Chartmill
In today's session, there are S&P500 stocks with remarkable trading volume. ↗
Via Chartmill
Top S&P500 movers in Friday's session ↗
Via Chartmill
What's going on in today's session: S&P500 gap up and gap down stocks ↗
Via Chartmill
ResMed (NYSE:RMD) Q4 Results Inline with Estimates; Stock Slips 1.9% ↗
Via Chartmill
ResMed Inc (NYSE:RMD) Offers a Quality Dividend Built on Strong Profitability and Financial Health ↗
Via Chartmill
Which S&P500 stocks are moving before the opening bell on Friday? ↗
Via Chartmill
News headline image
RMD Q2 Deep Dive: Margin Pressures Weigh Despite Product Momentum and Portfolio Shifts
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP ... 
Via StockStory
Topics Economy
News headline image
ResMed (NYSE:RMD) Posts Q2 CY2026 Sales In Line With Estimates But Stock Drops
Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q2 CY2026, with sales up 8.6% year on year to $1.46 billion. Its non-GAAP ... 
Via StockStory
News headline image
Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026
From Resmed, Inc.
Via GlobeNewswire
ResMed Inc (NYSE:RMD) Builds on a Quality Foundation with Strong Profitability and Cash Conversion ↗
Via Chartmill
News headline image
ResMed (RMD) Q2 Earnings: What To Expect
Medical device company ResMed (NYSE:RMD) will be announcing earnings results this Thursday after the bell. Here’s what to expect. ResMed beat analysts’ reven... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Find Risky
Generating cash is essential for any business, but not all cash-rich companies are great investments. Some produce plenty of cash but fail to allocate it eff... 
Via StockStory
News headline image
3 Large-Cap Stocks to Consider Right Now
Large-cap stocks have the power to shape entire industries thanks to their size and widespread influence. With such vast footprints, however, finding new are... 
Via StockStory
News headline image
3 Cash-Heavy Stocks to Research Further
A clean balance sheet can signal disciplined management and stability. It also means a company can expand and thrive without relying on borrowed capital. Not... 
Via StockStory
News headline image
2 Mid-Cap Stocks with Exciting Potential and 1 We Ignore
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the man... 
Via StockStory
What's going on in today's session: S&P500 movers ↗
Via Chartmill
Gapping S&P500 stocks in Wednesday's session ↗
Via Chartmill
News headline image
Resmed Announces Agreement to Sell MatrixCare Business
Sharpens Resmed’s focus on high-growth sleep and connected care markets 
From Resmed, Inc.
Via GlobeNewswire
Top S&P500 movers in Monday's session ↗
Via Chartmill
News headline image
Why ResMed (RMD) Stock Is Trading Up Today
What Happened? Shares of medical device company ResMed (NYSE:RMD) jumped 3.7% in the afternoon session after it was added to Goldman Sachs' APAC Conviction L... 
Via StockStory
News headline image
Resmed to Report Fourth Quarter Fiscal 2026 Earnings on August 6, 2026
From Resmed, Inc.
Via GlobeNewswire
News headline image
1 Oversold Stock Primed to Rebound and 2 We Find Risky
The past year hasn’t been kind to the stocks featured in this article. Each has tumbled to its lowest point in 12 months, leaving investors to decide whether... 
Via StockStory
Topics Bonds
News headline image
Here’s How Much You Would Have Made Owning ResMed Stock In The Last 20 Years ↗
ResMed (NYSE:RMD) has outperformed the market over the past 20 years by 1.89% on an annualized basis producing an average annual return ... 
Via Benzinga
News headline image
Stocks making big moves yesterday: Nubank, Ocular Therapeutix, Mondelez, ResMed, and Sonos
Check out the companies making headlines yesterday: Nubank (NYSE:NU): Digital banking platform Nubank (NYSE:NU) rose by 3.2% on Wednesday after the company r... 
Via StockStory
Topics Economy
News headline image
Why ResMed (RMD) Shares Are Falling Today
What Happened? Shares of medical device company ResMed (NYSE:RMD) fell 4.5% in the afternoon session after Morgan Stanley downgraded the stock to Equalweight... 
Via StockStory
Topics Artificial Intelligence Economy
Stay informed with the top movers within the S&P500 index on Wednesday. ↗
Via Chartmill
News headline image
3 Big Reasons RMD Should Be On Your Watchlist
ResMed’s stock price has taken a beating over the past six months, shedding 26.3% of its value and falling to $185.29 per share. This may have investors wond... 
Via StockStory
News headline image
Resmed Completes Acquisition of Noctrix Health, Expanding Clinical Sleep Health Portfolio
Acquisition adds Nidra® Tonic Motor Activation (TOMAC) Therapy, an FDA De Novo classified, nonpharmacologic treatment designed to address moderate-to-severe Restless Legs Syndrome (RLS). 
From Resmed, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.